These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12542477)

  • 21. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
    Mullen CA; Petropoulos D; Roberts WM; Rytting M; Zipf T; Chan KW; Culbert SJ; Danielson M; Jeha SS; Kuttesch JF; Rolston KV
    Cancer; 1999 Jul; 86(1):126-34. PubMed ID: 10391572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors.
    Rossini F; Pioltelli P; Mingozzi S; Bregani R; Viganó F; Bolis S; Casaroli I; Lanzi E; Pogliani EM; Corneo G
    Support Care Cancer; 1994 Jul; 2(4):259-65. PubMed ID: 8087446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefepime and amikacin as empirical therapy in patients with febrile neutropaenia: a single-centre phase II prospective survey.
    Mebis J; Vandeplassche S; Goossens H; Berneman ZN
    Acta Clin Belg; 2009; 64(1):35-41. PubMed ID: 19317239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial.
    Pico JL; Marie JP; Chiche D; Guiguet M; Andremont A; Lapierre V; Richet H; Tancrede C; Lagrange P; Hayat M
    Eur J Med; 1993 May; 2(5):275-80. PubMed ID: 8252157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia.
    Santhosh-Kumar CR; Ajarim DS; Harakati MS; al Momen AK; al Mohareb F; Zeitany RG
    J Infect; 1992 Jul; 25(1):11-9. PubMed ID: 1365011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
    Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
    J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes.
    Jeddi R; Achour M; Amor RB; Aissaoui L; Bouterâa W; Kacem K; Lakhal RB; Abid HB; BelHadjAli Z; Turki A; Meddeb B
    Hematology; 2010 Feb; 15(1):28-32. PubMed ID: 20132659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-risk febrile neutropenia in a medical oncology unit.
    Leong DC; Kinlay S; Ackland S; Bonaventura A; Stewart JF
    Aust N Z J Med; 1997 Aug; 27(4):403-7. PubMed ID: 9448881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftriaxone plus amikacin in neutropenic patients: a report on 100 cases.
    Blanc C; Pollet JP; Bauters F
    Chemotherapy; 1991; 37(5):382-8. PubMed ID: 1804600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.
    Kebudi R; Görgün O; Ayan I; Gürler N; Akici F; Töreci K
    Med Pediatr Oncol; 2001 Apr; 36(4):434-41. PubMed ID: 11260566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.
    El-Maghraby SM; Moneer MM; Ismail MM; Shalaby LM; El-Mahallawy HA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):131-6. PubMed ID: 17356388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies.
    Menichetti F; Del Favero A; Bucaneve G; Aversa F; Fiorio M
    Br J Haematol; 1990 Dec; 76 Suppl 2():45-8. PubMed ID: 2149052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.